Batra A, Rigo R, Sheka D, Cheung WY. Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. World J Gastrointest Oncol 2020; 12(6): 604-618 [PMID: 32699576 DOI: 10.4251/wjgo.v12.i6.604]
Corresponding Author of This Article
Winson Y Cheung, MD, Doctor, Professor, Department of Oncology, University of Calgary, 1331 – 29 Street NW, Calgary, Alberta T2N 4N2, Canada. winson.cheung@ahs.ca
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jun 15, 2020; 12(6): 604-618 Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.604
Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
Atul Batra, Rodrigo Rigo, Dropen Sheka, Winson Y Cheung
Atul Batra, Rodrigo Rigo, Dropen Sheka, Department of Medicine, Tom Baker Cancer Centre, Calgary, Alberta T2N 1N4, Canada
Winson Y Cheung, Department of Oncology, University of Calgary, Calgary, Alberta T2N 4N2, Canada
Author contributions: Batra A, Rigo R, Sheka D and Cheung WY collected the data and wrote the paper.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Winson Y Cheung, MD, Doctor, Professor, Department of Oncology, University of Calgary, 1331 – 29 Street NW, Calgary, Alberta T2N 4N2, Canada. winson.cheung@ahs.ca
Received: February 24, 2020 Peer-review started: February 24, 2020 First decision: April 9, 2020 Revised: May 8, 2020 Accepted: May 29, 2020 Article in press: May 29, 2020 Published online: June 15, 2020 Processing time: 111 Days and 15.4 Hours
Core Tip
Core tip: Use of adjuvant chemotherapy consisting of fluoropyrimidines with/without oxaliplatin has improved survival outcomes for patients with resected colon cancer, especially in those with stage III disease. However, older adults are often not given the opportunity to benefit from chemotherapy after surgery because undertreatment may occur due to various patient and physician related factors. The issue is further compounded by the limited representation of older adults in clinical trials, resulting in underpowered subgroup analyses that do not provide conclusive answers regarding the utility of adjuvant chemotherapy in the advanced age group. We herein review the role of adjuvant chemotherapy in early stage colon cancer, specifically in the context of the older subpopulation, by focusing on both data from clinical trials and data from real-world evidence sources.
